Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

Journal of the American College of Cardiology

Volumn 40, Issue 12, 2002, Pages 2125-2134

  Davidson, Michael H ^a   McGarry, Thomas ^b   Bettis, Robert ^c   Melani, Lorenzo ^d   Lipka, Leslie J ^d   LeBeaut, Alexandre P ^d   Suresh, Ramachandran ^d   Sun, Steven ^d   Veltri, Enrico P ^d  

^a RADIANT RESEARCH   (United States)

^b Oklahoma Foundation for Cardiovascular Research   (United States)

^c Clinical Research Advantage   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLECYSTECTOMY; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEPATOMEGALY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0037132598     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02610-4     Document Type: Article

References (22)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
3. Fruchart J-C, Brewer HB Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Am J Cardiol 1998;81:912-7.
4. Backman JT, Kyrklund C, Kivistö KT, Wang J-S, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9.
5. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J 2001;94:1023-6.
6. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998;19:355-71.
7. van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157-63.
8. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54.
9. Knopp RH, Bays H, Manion CV, et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins (abstr). Atherosclerosis 2001;2 Suppl:90.
10. Kosoglou T, Meyer I, Musiol B, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin (abstr). Atherosclerosis 2000;151:135.
11. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. New York Heart Association. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis. 6th ed. Boston, MA: Little, Brown, 1964:114.
14. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
15. ZOCOR (simvastatin). In: Physicians' Desk Reference. 53rd Ed. Montvale, NJ: Medical Economics Company, 2001:2219-23.
16. Ballantyne C, Houri J, Notarbartolo A, et al. Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia (abstr). J Am Coll Cardiol 2002;39 Suppl A:227A.
17. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151:43-9.
18. Tolman KG. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000;85:15E-19E.
19. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80.
20. Dujovne CA. Side effects of statins: Hepatitis versus "transaminitis"-Myositis versus "CPKitis." Am J Cardiol 2002;89:1411-3.
21. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900.
22. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000;23:197-213.